Metallo-Drugs: Development and Action of Anticancer Agents
Ed. by Sigel, Astrid / Sigel, Helmut / Freisinger, Eva / Sigel, Roland K.O.
With contrib. by Riddell, Imogen / Lippard, Stephen J. / Brabec, Victor / Kasparkova, Jana / Menon, Vijay / Farrell, Nicholas P. / Venkatesh, V. / Sadler, Peter J. / Gorle, Anil K. / Peterson, Erica J. / Berners-Price, Susan / Alessio, Enzo / Messori, Luigi / Babak, Maria V. / Ang, Wee Han / Casini, Angela / Sun, Raymond Wai-Yin / Ott, Ingo / Tshuva, Edit / Miller, Maya / Crans, Debbie / Yan, Lining / Haase, Allison / Yang, Xiaogai / Chitambar, Christopher / Cardo, Lucia / Hannon, Michael John / Vilar, Ramon / Sullivan, Matthew P. / Holtkamp, Hannah U. / Hartinger, Christian G. / Schatzschneider, Ulrich / Thévenod, Frank / Denoyer, Delphine / Clatworthy, Sharnel A. S. / Cater, Michael / Ziliotto, Silvia / Ogle, Olivia / Taylor, Kathryn M.
Series:Metal Ions in Life Sciences 18
- eBook (PDF)
- Publication Date:
- February 2018
- Copyright year:
17. Targeting Zinc(II) Signalling to Prevent Cancer
Ziliotto, Silvia / Ogle, Olivia / Taylor, Kathryn M.
Zinc is an important element that is gaining momentum as a potential target for cancer therapy. In recent years zinc has been accepted as a second messenger that is now recognized to be able to activate many signalling pathways within a few minutes of an extracellular stimulus by release of zinc(II) from intracellular stores. One of the major effects of this store release of zinc is to inhibit a multitude of tyrosine phosphatases which will prevent the inactivation of tyrosine kinases and hence, encourage further activation of tyrosine kinasedependent signalling pathways. Most of these signalling pathways are not only known to be involved in driving aberrant cancer growth, they are usually the main driving force. All this data together now positions zinc and zinc signalling as potentially important new targets to prevent aggressive cancer growth.
Silvia Ziliotto, Olivia Ogle, Kathryn M. Taylor (2018). 17. Targeting Zinc(II) Signalling to Prevent Cancer. In Astrid Sigel, Helmut Sigel, Eva Freisinger, Roland K.O. Sigel (Eds.), Metallo-Drugs: Development and Action of Anticancer Agents (pp. 507–530). Berlin, Boston: De Gruyter. https://doi.org/10.1515/9783110470734-023
Book DOI: https://doi.org/10.1515/9783110470734
Online ISBN: 9783110470734© 2018 Walter de Gruyter GmbH, Berlin/Munich/Boston